Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma.
D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D002273:Carcinogens; D000068579:Celecoxib; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D015232:Dinoprostone / Q000096:biosynthesis; D004357:Drug Synergism; D005260:Female; D005449:Fluorenes / Q000494:pharmacology; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D007930:Leucine / Q000031:analogs & derivatives* / Q000494:pharmacology; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000201:enzymology / Q000378:metabolism / Q000517:prevention & control*; D008770:Methylnitrosourea; D015230:Prostaglandin D2 / Q000031:analogs & derivatives* / Q000096:biosynthesis; D011451:Prostaglandin-Endoperoxide Synthases / Q000096:biosynthesis; D011720:Pyrazoles; D051381:Rats; D017207:Rats, Sprague-Dawley; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists* / Q000096:biosynthesis; D013449:Sulfonamides / Q000494:pharmacology; D014157:Transcription Factors / Q000819:agonists* / Q000096:biosynthesis
C477819:15-deoxyprostaglandin J2; D016588:Anticarcinogenic Agents; D002273:Carcinogens; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D005449:Fluorenes; D007527:Isoenzymes; D011720:Pyrazoles; D018160:Receptors, Cytoplasmic and Nuclear; D013449:Sulfonamides; D014157:Transcription Factors; C082231:N-(fluorenyl-9-methoxycarbonyl)leucine; D008770:Methylnitrosourea; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases; D007930:Leucine; D000068579:Celecoxib; D015232:Dinoprostone; D015230:Prostaglandin D2